Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Income from Continuing Operations (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Income from Continuing Operations for 6 consecutive years, with 54921000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 27.74% to 54921000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 275703000.0, a 18.36% increase, with the full-year FY2025 number at 275703000.0, up 18.36% from a year prior.
  • Income from Continuing Operations was 54921000.0 for Q4 2025 at Relay Therapeutics, up from 73984000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 42184000.0 in Q1 2021 to a low of 193400000.0 in Q2 2021.
  • A 5-year average of 80488300.0 and a median of 76405500.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: tumbled 623.78% in 2021, then surged 60.29% in 2022.
  • Relay Therapeutics' Income from Continuing Operations stood at 67456000.0 in 2021, then fell by 0.03% to 67479000.0 in 2022, then dropped by 23.74% to 83496000.0 in 2023, then grew by 8.97% to 76005000.0 in 2024, then grew by 27.74% to 54921000.0 in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Income from Continuing Operations are 54921000.0 (Q4 2025), 73984000.0 (Q3 2025), and 69742000.0 (Q2 2025).